Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Haplo-identical transplantation in patients with myelofibrosis, a phase 2 prospective multicentric study

View Full Paper
Ask AI
Bookmark
Share

Authors

MRMarie RobinMRMarie-Thérèse RubioFSFelipe Suarez

Discussion

Loading...

Member takes

Overview

Phase 2 trial shows improved one-year relapse-free survival in myelofibrosis using haplo-identical donors, indicating viability over historical standards.

Key Points

  • One-year relapse and rejection-free survival reached 64.3% after haplo-identical transplantation in myelofibrosis patients, showing significant improvement.
  • The cumulative incidence of grade 2-4 acute GVHD was 64.3%, suggesting a need for monitoring post-transplant complications closely.
  • Assessment of 28 patients underwent haplo-identical stem cell transplantation, where significant early outcomes were achieved by various metrics, including survival rates.
  • Non-relapse mortality emerged as a key challenge post-transplant, mainly attributed to acute GVHD and infections, highlighting areas for future research.

Cite This Study

Robin et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e509https://doi.org/10.1182/blood-2025-506
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Allogeneic hematopoietic stem cell transplantation for myelofibrosis; Patterns, treatment and outcome after relapse and long-term follow up.2025
  2. 2An evolving landscape – how changing conditioning regimes can improve myelofibrosis transplant outcomes.2025
  3. 3Allogeneic hematopoietic stem cell transplantation for hematological malignancies using nonmyeloablative fludarabine, cyclophosphamide, 200 centigray total body irradiation, and post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil for graft-versus-host disease prophylaxis is associated with low non-relapse mortality.2025
  4. 4Mismatched unrelated and haploidentical transplant with post-transplant cyclophosphamide-based graft versus host disease prophylaxis are effective for myelofibrosis2025
  5. 5Haploidentical hematopoietic stem cell transplantation using low-dose alemtuzumab is effective for standard-risk hematological malignancies2025